Company Overview and News

 
Week In Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund

2017-05-07 seekingalpha
Ping An Insurance Group (OTCPK:PNGAY) (OTCPK:PIAIF) (HK: 2318; SHA: 601318), China's largest insurer by market value, announced plans to launch a $1 billion international fund that will invest in fin-tech and healthcare startups. Ping An is already a player in the fin-tech area with Lufax, China's biggest peer-to-peer lending and wealth management platform. In healthcare, the company offers Ping An Good Doctor, a mobile app, which has 140 million users and is, says Ping An, the first healthcare stop for many people in China.

 
Uni-Bio Science Launches Best-in-Class Oral Anti-Diabetic Drug Mitiglinide Branded Bokangtai)

2017-05-04 marketwired
HONG KONG, CHINA--(Marketwired - May 4, 2017) -  Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group") (HKSE: 690) today announced that, with the exclusive global rights to manufacture and commercialize Mitiglinide acquired from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh") in 2015, it is launching this new oral anti-diabetic drug (OAD) under the registered brand name (Bokangtai) today in Fujian province, subsequent to the drug being included in the 2017 NRDL.

 
Uni-Bio Science in Multiple Drug Co-development Deal with Beijing Sun-Novo

2016-12-01 marketwired
Extended R&D Collaboration of Oral Diabetes Drugs Promising to Meet Unmet Needs Complements the Group's R&D Capabilities and Diabetes Treatment Portfolio

 
Uni-Bio Science in Multiple Drug Co-development Deal with Beijing Sun-Novo

2016-12-01 business.asiaone
HONG KONG, CHINA - Media OutReach - 1 December 2016 -- Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has signed a multiple drug co-development deal with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. ("Beijing Sun-Novo"), a China-based company engaged in research and development (R&D), manufacturing and commercialization of pharmaceutical products, to extend Uni-Bio's current R&D capabilities in small molecule drug development.

 
Uni-Bio Science Group Forges Strategic Alliance with LUQA

2016-11-14 marketwired
Joins Forces with LUQA in Co-promoting Drugs and Medical Devices for Treatment of Dermatological Disorders in Mainland China

 
Uni-Bio Science Group Forges Strategic Alliance with LUQA

2016-11-14 business.asiaone
HONG KONG, CHINA - Media OutReach - 14 November 2016 - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has established a strategic partnership with Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. ("LUQA"), a China-focused specialty pharmaceutical company, to conduct co-promotion or/ and co-marketing of dermatology drugs in Mainland China, enabling the Group to immediately expand its income stream and generate cash flow.

 
Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

2016-11-09 prnewswire
Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

 
Week In Review: Hepalink Invests $13 Million In Canada's OncoQuest

2016-09-18 seekingalpha
Shenzhen Hepalink Pharma (SHZ: 002399) closed a $13 million investment in OncoQuest, the oncology subsidiary of Canada's Quest PharmaTech (TSX-V: QPT) (OTC:QPTFF), giving Hepalink a 42% stake in OncoQuest (see story). OncoQuest is developing several immunotherapeutic antibodies to treat cancer. The two companies are also reported to be in talks on a $5 million JV to develop OncoQuest's products in China.

 
Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

2016-08-23 prnewswire
Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

 
Week In Review: China Bridge Capital Announces $1.5 Billion Precision Medicine Fund

2016-07-17 seekingalpha
China Bridge Capital, a Beijing financial services firm, invested $45 million in iCarbonX, the big data/AI healthcare start-up that raised $155 million in a Series A at a $1 billion valuation earlier this year. iCarbonX was founded by Jun Wang, formerly CEO of BGI, China's giant gene sequencing company. China Bridge also plans to raise $1.5 billion for an investment fund that acquires precision healthcare assets, a focus area for iCarbonX.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...